Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD) in Chile: lessons learned from challenging cases

Jorge Guzmán,Francisco Vera,Bernardita Soler,Reinaldo Uribe-San-Martin,Lorena García,Adolfo Del-Canto,Andrea Schlatter, Mauricio Salazar,Fernando Molt,Karla Ramirez, José Marín,Carolina Pelayo,Juan Pablo Cruz,Sebastián Bravo-Grau,Claudia Cárcamo,Ethel Ciampi

Multiple Sclerosis and Related Disorders（2023）

引用 1|浏览12

暂无评分

摘要

•First multicentric observational longitudinal study including MOGAD patients in Chile.•35 patients, 71% women, wide range of disease onset (1–68 years), 23% paediatric.•Relapsing patients (34%) were younger (25 vs 34 years) and with longer follow-up.•2 patients (5.7%) with concomitant CSF anti-NMDAR-IgG and encephalitis/seizures.•Median EDSS was 1.5 (0–6) with a median follow up of 24 months (12–348).

查看译文

关键词

MOGAD,Myelin Oligodendrocyte Glycoprotein,MOG,NMOSD,Demyelinating disease,MRI,NMDAR,Relapse,Rituximab,Satralizumab

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要